Paul J. Clancy - Oct 26, 2021 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
Director
Signature
/s/ Chris Frankenfield attorney-in-fact for Paul Clancy
Stock symbol
XLO
Transactions as of
Oct 26, 2021
Transactions value $
$0
Form type
4
Date filed
10/26/2021, 05:01 PM
Previous filing
Oct 21, 2021
Next filing
Jan 4, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLO Stock Option (right to buy) Award $0 +44K $0.00 44K Oct 26, 2021 Common Stock 44K $5.51 Direct F1
transaction XLO Stock Option (right to buy) Award $0 +65.5K $0.00 65.5K Oct 26, 2021 Common Stock 65.5K $5.89 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 23, 2020, the reporting person was granted an option to purchase 44,033 shares of common stock of the Company, the vesting of which was contingent upon the closing of the Company's initial public offering ("IPO"). The Company's IPO closed as of October 26, 2021. On October 26, 2021, 13,760 shares underlying the award vested and the remainder will vest in equal monthly installments until July 16, 2024.
F2 On March 11, 2021, the reporting person was granted an option to purchase 65,528 shares of common stock of the Company, the vesting of which was contingent upon the closing of the Company's IPO. The Company's IPO closed as of October 26, 2021. On October 26, 2021, 20,477 shares underlying the option vested and the remainder will vest in equal monthly installments until July 16, 2024.